EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN

Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain sy...

Full description

Bibliographic Details
Main Authors: R. A. Zukov, O. P. Bobrova, G. N. Gildeeva, D. V. Butuzova, E. A. Ershova
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2019-09-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/1138
_version_ 1797875817000206336
author R. A. Zukov
O. P. Bobrova
G. N. Gildeeva
D. V. Butuzova
E. A. Ershova
author_facet R. A. Zukov
O. P. Bobrova
G. N. Gildeeva
D. V. Butuzova
E. A. Ershova
author_sort R. A. Zukov
collection DOAJ
description Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO.
first_indexed 2024-04-10T01:53:37Z
format Article
id doaj.art-bdb8f4f078394d8a9679f47da15c472c
institution Directory Open Access Journal
issn 1814-4861
2312-3168
language Russian
last_indexed 2024-04-10T01:53:37Z
publishDate 2019-09-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj.art-bdb8f4f078394d8a9679f47da15c472c2023-03-13T09:05:52ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682019-09-01184273310.21294/1814-4861-2019-18-4-27-33654EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAINR. A. Zukov0O. P. Bobrova1G. N. Gildeeva2D. V. Butuzova3E. A. Ershova4ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России; КГБУЗ «Красноярский краевой клинический онкологический диспансер им. А.И. Крыжановского»ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России; КГБУЗ «Красноярский краевой клинический онкологический диспансер им. А.И. Крыжановского»ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииООО «Медикал девелопмент эдженси»ФГУП «Московский эндокринный завод»Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO.https://www.siboncoj.ru/jour/article/view/1138хронический болевой синдромонкологияморфина гидрохлоридэффективностьбезопасность
spellingShingle R. A. Zukov
O. P. Bobrova
G. N. Gildeeva
D. V. Butuzova
E. A. Ershova
EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
Сибирский онкологический журнал
хронический болевой синдром
онкология
морфина гидрохлорид
эффективность
безопасность
title EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
title_full EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
title_fullStr EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
title_full_unstemmed EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
title_short EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN
title_sort efficacy and safety of morphine hydrochloride in cancer patients with chronic pain
topic хронический болевой синдром
онкология
морфина гидрохлорид
эффективность
безопасность
url https://www.siboncoj.ru/jour/article/view/1138
work_keys_str_mv AT razukov efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain
AT opbobrova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain
AT gngildeeva efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain
AT dvbutuzova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain
AT eaershova efficacyandsafetyofmorphinehydrochlorideincancerpatientswithchronicpain